Nevertheless, the dose-dependent reduction in the liver injury biomarkers ALT and CK-18 caspase in the absence of changes in BMI observed in the 3–10 mg BI 1467335 groups provides further support for adequate target engagement and proof-of-mechanism in patients with NASH. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.